Danaher: Christopher Riley
Danaher has appointed Christopher Riley to take over as executive VP of biotechnology, effective Jan. 1, 2024. He is currently VP and group executive of Danaher's Life Sciences business, responsible for genomic medicines, and previously was VP and group executive for the firm's Diagnostics business. He has held various roles across multiple Danaher subsidiaries, including Beckman Coulter. Riley previously worked as a manager for the Boston Consulting Group.